Abstract

A treatment target for progressive left ventricular (LV) remodeling prevention following myocardial infarction (MI) is to affect structural changes directly within the MI region. One approach is through targeted injection...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Targeted injection of a biocomposite material alters macrophage and fibroblast phenotype and function following myocardial infarction: relation to left ventricular remodeling.
Jeremy R Mcgarvey ... Robert C Gorman
The Journal of pharmacology and experimental therapeutics | VOL. 350
Jeremy R Mcgarvey, et. al.Jeremy R Mcgarvey ... Robert C Gorman
14 Jul 2014
Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications.
R English Chapman ... Francis G Spinale
American Journal of Physiology-heart and Circulatory Physiology | VOL. 286
R English Chapman, et. al.R English Chapman ... Francis G Spinale
01 Jan 2004
Author response: new therapies for reducing post-myocardial left ventricular remodeling.
Francis G Spinale ... Jason A Burdick
Annals of Translational Medicine | VOL. 3
Francis G Spinale, et. al.Francis G Spinale ... Jason A Burdick
09 Jun 2015
Commentary: Elucidating the mechanisms underlying left ventricular function recovery in patients with ischemic heart failure undergoing surgical remodeling: Physiology versus Empiricism
Giuseppe Ambrosio ... Erberto Carluccio
The Journal of thoracic and cardiovascular surgery | VOL. 165
Giuseppe Ambrosio, et. al.Giuseppe Ambrosio ... Erberto Carluccio
05 Mar 2021
View more papers

More From: BMJ (Clinical research ed.)

Paper Title
Journal
Date
Author
Four year medical degrees in the UK
Gabrielle M Finn ... Paul A Tiffin
BMJ (Clinical research ed.) | VOL. 386
Gabrielle M Finn, et. al.Gabrielle M Finn ... Paul A Tiffin
01 Aug 2024
Scarlett McNally: We can all do better to encourage diversity to benefit staff and patients
Scarlett Mcnally
BMJ (Clinical research ed.) | VOL. 386
Scarlett McnallyScarlett Mcnally
01 Aug 2024
V Craig Jordan: pharmacologist and father of tamoxifen
Janet Fricker
BMJ (Clinical research ed.) | VOL. 386
Janet FrickerJanet Fricker
01 Aug 2024
Covid-19: “Substantial psychiatric burden” is still seen three years after infection, researchers find
Jacqui Wise
BMJ (Clinical research ed.) | VOL. 386
Jacqui WiseJacqui Wise
01 Aug 2024
View more papers